For PD-L1-positive patients (defined as tumor PD-L1 expression of ≥1%), there was also a statistically significant advantage in survival at 6 months (75.3% vs. 56.7%; HR 0.55; 95% CI, 0.39–0.79). The gene discussed is CD274; the disease is neoplasm.